Showing results (131-140 of 290) with videos related to
Sort By:
Pageof 29
Gynecologic Oncology|March 27, 2016
Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancersLorna Rodriguez-Rodriguez, Kim M Hirshfield, Veronica Rojas, et al.Science Translational Medicine|October 7, 2011
Survival and death signals can predict tumor response to therapy after oncogene inactivationPhuoc T Tran, Pavan K Bendapudi, H Jill Lin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung CancerJessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
<i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K<b>α</b> InhibitorsSarah Croessmann, Jonathan H Sheehan, Kyung-Min Lee, et al.The Oncologist|June 29, 2019
<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic LandscapeSamuel J Klempner, Russell Madison, Vivek Pujara, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinibM Catherine Pietanza, Thomas James Lynch, Primo N Lara, et al.Plos Genetics|December 21, 2016
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma GenomeOlivia M Padovan-Merhar, Pichai Raman, Irina Ostrovnaya, et al.The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumorsChristopher G Azzoli, Lee M Krug, Jorge Gomez, et al.Oncology|September 23, 2020
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNASaranya Akumalla, Russell Madison, Douglas I Lin, et al.Pageof 29